2.95
+18.47%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About BioInvent International
Its shares trade on Nasdaq Stockholm under the ticker BINV.ST. It has been listed since 12 June 2001. In the fiscal year to 31 December 2025, it reported revenue of SEK 226.5m and a net loss of SEK 332.9m. At that date it held total assets of SEK 671.2m and shareholders' equity of SEK 557.6m.
BioInvent International AB engages in the research and development of immunomodulating antibodies for the treatment of cancer. The company is headquartered in Lund, Skane. The company went IPO on 2001-06-12. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The firm has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Jun 2001
- Employees
- 73
- Website
- bioinvent.se ↗
Leadership
Pay as last reported
- Mr. Leonard KruimerIndependent Chairman of the BoardSEK 782,000
- Dr. Martin WelschofChief Executive OfficerSEK 5.1m
- Mr. Stefan EricssonChief Financial Officer, since 2016
- Ms. Marie MooresChief Operating Officer
- Mr. Ashley RobinsonSenior Vice President - Strategy & Finance
- Mr. Kristoffer HanssonSenior Vice President - Technical Operations
- Dr. Ingunn LindvigSenior Vice President - Regulatory Affairs
- Mr. Bjoern FrendeusChief Scientific Officer, since 2018SEK 2.4m
- Dr. Andres McAllisterChief Medical Officer
- Ms. Sylvie RyckebuschChief Business Officer
- Ms. Natalie BernerDirector
- Ms. Elin BirgerssonDirector, Employee Representative
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 45
- Environment
- 34
- Social
- 47
- Governance
- 53
- Women in the workforce
- 73%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Innovative and diverse product portfolio, including antibody-based therapeutics.
- Strong research and development capabilities, facilitating discovery of novel drug candidates.
- Robust intellectual property rights, safeguarding inventions and promoting competitiveness.
- Established collaborations with reputable pharmaceutical companies, enhancing market reach and potential partnerships.
Weaknesses
- Relatively small scale and limited resources compared to major industry players.
- Dependency on key clients and partners, which may pose risks to revenue and growth prospects.
- Potential vulnerability to changes in regulatory environment and reimbursement policies.
- Limited geographical presence, constraining market opportunities in certain regions.
Opportunities
- Growing demand for targeted therapies and precision medicine, offering market expansion opportunities.
- Increasing prevalence of chronic diseases, creating higher demand for effective treatment options.
- Potential for strategic collaborations and partnerships, enabling access to complementary expertise and resources.
- Advances in technological capabilities, such as antibody engineering, opening new avenues for innovation.
Threats
- Intense competition from larger pharmaceutical companies with greater resources and market presence.
- Uncertainty surrounding regulatory approvals and clinical trial outcomes, impacting product development timelines.
- Risks associated with potential side effects or adverse events related to newly developed therapeutics.
- Volatility in global economic conditions and exchange rates, affecting financial stability and investment decisions.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.